DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo
Tatyana N. Zamay
1
,
Olga S. Kolovskaya
2
,
Yury E. Glazyrin
1
,
Galina S. Zamay
1
,
Svetlana A. Kuznetsova
3
,
Ekaterina A. Spivak
2
,
Mohamed Wehbe
4
,
Mohamed Wehbe
4
,
Anna G. Savitskaya
2
,
Olga A. Zubkova
2
,
Anastasia Kadkina
2
,
Xiaoyan Wang
4
,
Darija Muharemagic
4
,
Anna Dubynina
2
,
Yuliya Sheina
5
,
Alla B. Salmina
1
,
Anna S. Zamay
1, 3
5
Center for Reproductive Medicine, Krasnoyarsk, Russia.
|
Publication type: Journal Article
Publication date: 2014-01-12
scimago Q1
wos Q1
SJR: 1.499
CiteScore: 8.2
Impact factor: 4.7
ISSN: 21593337, 21593345
PubMed ID:
24410722
Drug Discovery
Biochemistry
Molecular Biology
Genetics
Molecular Medicine
Abstract
In recent years, new prospects for the use of nucleic acids as anticancer drugs have been discovered. Aptamers for intracellular targets can regulate cellular functions and cause cell death or proliferation. However, intracellular aptamers have limited use for therapeutic applications due to their low bioavailability. In this work, we selected DNA aptamers to cell organelles and nucleus of cancer cells, and showed that an aptamer NAS-24 binds to vimentin and causes apoptosis of mouse ascites adenocarcinoma cells in vitro and in vivo. To deliver the aptamer NAS-24 inside cells, natural polysaccharide arabinogalactan was used as a carrier reagent. The mixture of arabinogalactan and NAS-24 was injected intraperitonealy for 5 days into mice with adenocarcinoma and inhibited adenocarcinoma growth more effectively than free arabinogalactan or the aptamer alone. The use of aptamers to intracellular targets together with arabinogalactan becomes a promising approach for anticancer therapy.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
|
|
|
Molecules
5 publications, 10.42%
|
|
|
Cancers
3 publications, 6.25%
|
|
|
International Journal of Molecular Sciences
3 publications, 6.25%
|
|
|
Molecular Therapy
2 publications, 4.17%
|
|
|
International Journal of Pharmaceutics
2 publications, 4.17%
|
|
|
Molecular Therapy - Nucleic Acids
1 publication, 2.08%
|
|
|
Current Drug Delivery
1 publication, 2.08%
|
|
|
Oncotarget
1 publication, 2.08%
|
|
|
Nucleic Acid Therapeutics
1 publication, 2.08%
|
|
|
BioTechniques
1 publication, 2.08%
|
|
|
Cells
1 publication, 2.08%
|
|
|
Life
1 publication, 2.08%
|
|
|
Pharmaceutics
1 publication, 2.08%
|
|
|
Pharmaceutical Research
1 publication, 2.08%
|
|
|
BioDrugs
1 publication, 2.08%
|
|
|
Journal of Controlled Release
1 publication, 2.08%
|
|
|
International Immunopharmacology
1 publication, 2.08%
|
|
|
Experimental Cell Research
1 publication, 2.08%
|
|
|
Cancer Letters
1 publication, 2.08%
|
|
|
Advanced Drug Delivery Reviews
1 publication, 2.08%
|
|
|
ACS Pharmacology & Translational Science
1 publication, 2.08%
|
|
|
Industrial & Engineering Chemistry Research
1 publication, 2.08%
|
|
|
Analytical Chemistry
1 publication, 2.08%
|
|
|
RSC Advances
1 publication, 2.08%
|
|
|
Nanotechnology in the Life Sciences
1 publication, 2.08%
|
|
|
Frontiers in Molecular Biosciences
1 publication, 2.08%
|
|
|
Nuclear Medicine Communications
1 publication, 2.08%
|
|
|
Cancer and Metastasis Reviews
1 publication, 2.08%
|
|
|
Progress in Molecular Biology and Translational Science
1 publication, 2.08%
|
|
|
1
2
3
4
5
|
Publishers
|
2
4
6
8
10
12
14
|
|
|
Elsevier
14 publications, 29.17%
|
|
|
MDPI
14 publications, 29.17%
|
|
|
Springer Nature
4 publications, 8.33%
|
|
|
American Chemical Society (ACS)
3 publications, 6.25%
|
|
|
Royal Society of Chemistry (RSC)
2 publications, 4.17%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 2.08%
|
|
|
Impact Journals
1 publication, 2.08%
|
|
|
Mary Ann Liebert
1 publication, 2.08%
|
|
|
Taylor & Francis
1 publication, 2.08%
|
|
|
IntechOpen
1 publication, 2.08%
|
|
|
Wiley
1 publication, 2.08%
|
|
|
Frontiers Media S.A.
1 publication, 2.08%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 2.08%
|
|
|
2
4
6
8
10
12
14
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
48
Total citations:
48
Citations from 2024:
3
(6%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Zamay T. N. et al. DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo // Nucleic Acid Therapeutics. 2014. Vol. 24. No. 2. pp. 160-170.
GOST all authors (up to 50)
Copy
Zamay T. N., Kolovskaya O. S., Glazyrin Y. E., Zamay G. S., Kuznetsova S. A., Spivak E. A., Wehbe M., Wehbe M., Savitskaya A. G., Zubkova O. A., Kadkina A., Wang X., Muharemagic D., Dubynina A., Sheina Y., Salmina A. B., Berezovski M. V., Zamay A. S. DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo // Nucleic Acid Therapeutics. 2014. Vol. 24. No. 2. pp. 160-170.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1089/nat.2013.0471
UR - https://doi.org/10.1089/nat.2013.0471
TI - DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo
T2 - Nucleic Acid Therapeutics
AU - Zamay, Tatyana N.
AU - Kolovskaya, Olga S.
AU - Glazyrin, Yury E.
AU - Zamay, Galina S.
AU - Kuznetsova, Svetlana A.
AU - Spivak, Ekaterina A.
AU - Wehbe, Mohamed
AU - Wehbe, Mohamed
AU - Savitskaya, Anna G.
AU - Zubkova, Olga A.
AU - Kadkina, Anastasia
AU - Wang, Xiaoyan
AU - Muharemagic, Darija
AU - Dubynina, Anna
AU - Sheina, Yuliya
AU - Salmina, Alla B.
AU - Berezovski, Maxim V.
AU - Zamay, Anna S.
PY - 2014
DA - 2014/01/12
PB - Mary Ann Liebert
SP - 160-170
IS - 2
VL - 24
PMID - 24410722
SN - 2159-3337
SN - 2159-3345
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2014_Zamay,
author = {Tatyana N. Zamay and Olga S. Kolovskaya and Yury E. Glazyrin and Galina S. Zamay and Svetlana A. Kuznetsova and Ekaterina A. Spivak and Mohamed Wehbe and Mohamed Wehbe and Anna G. Savitskaya and Olga A. Zubkova and Anastasia Kadkina and Xiaoyan Wang and Darija Muharemagic and Anna Dubynina and Yuliya Sheina and Alla B. Salmina and Maxim V. Berezovski and Anna S. Zamay},
title = {DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo},
journal = {Nucleic Acid Therapeutics},
year = {2014},
volume = {24},
publisher = {Mary Ann Liebert},
month = {jan},
url = {https://doi.org/10.1089/nat.2013.0471},
number = {2},
pages = {160--170},
doi = {10.1089/nat.2013.0471}
}
Cite this
MLA
Copy
Zamay, Tatyana N., et al. “DNA-Aptamer Targeting Vimentin for Tumor Therapy In Vivo.” Nucleic Acid Therapeutics, vol. 24, no. 2, Jan. 2014, pp. 160-170. https://doi.org/10.1089/nat.2013.0471.
Profiles